David Mountcastle Sells 7,179 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CFO David Mountcastle sold 7,179 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $25.03, for a total transaction of $179,690.37. Following the sale, the chief financial officer directly owned 214,847 shares of the company’s stock, valued at $5,377,620.41. This represents a 3.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

• On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The stock was sold at an average price of $25.00, for a total transaction of $30,150.00.
• On Thursday, April 2nd, David Mountcastle sold 5,566 shares of Privia Health Group stock. The shares were sold at an average price of $20.85, for a total transaction of $116,051.10.
• On Monday, March 16th, David Mountcastle sold 6,391 shares of Privia Health Group stock. The stock was sold at an average price of $22.11, for a total transaction of $141,305.01.
• On Friday, March 13th, David Mountcastle sold 6,565 shares of Privia Health Group stock. The stock was sold at an average price of $21.52, for a total value of $141,278.80.
• On Thursday, March 12th, David Mountcastle sold 6,453 shares of Privia Health Group stock. The shares were sold at an average price of $21.90, for a total value of $141,320.70.
• On Monday, March 9th, David Mountcastle sold 5,829 shares of Privia Health Group stock. The stock was sold at an average price of $22.84, for a total value of $133,134.36.
• On Friday, March 6th, David Mountcastle sold 5,177 shares of Privia Health Group stock. The stock was sold at an average price of $23.15, for a total value of $119,847.55.
• On Thursday, February 26th, David Mountcastle sold 5,361 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total value of $134,025.00.
• On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The shares were sold at an average price of $25.05, for a total value of $192,809.85.

Privia Health Group Stock Down 1.2%

NASDAQ:PRVA opened at $23.99 on Thursday. The company has a market cap of $3.01 billion, a P/E ratio of 141.12, a price-to-earnings-growth ratio of 1.51 and a beta of 0.96. Privia Health Group, Inc. has a twelve month low of $18.77 and a twelve month high of $26.51. The business has a 50 day moving average price of $22.68 and a two-hundred day moving average price of $23.35.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.21. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. The company had revenue of $541.17 million for the quarter, compared to the consensus estimate of $516.61 million. During the same period last year, the company earned $0.21 earnings per share. The firm’s revenue was up 17.4% compared to the same quarter last year. As a group, analysts anticipate that Privia Health Group, Inc. will post 0.37 earnings per share for the current fiscal year.

Key Stories Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Prior-quarter operating momentum: Privia beat expectations in its last report (Feb. 26) with $0.25 EPS vs. $0.04 est. and revenue of $541.2M (+17.4% YoY), which supports the view that growth and margin improvement are intact. Read More.
• Positive Sentiment: Analyst sentiment leans favorable: multiple firms (RBC, Truist, Jefferies, Wolfe) carry Buy/Outperform views and price targets near $31, indicating upside vs. the current share price. Read More.
• Neutral Sentiment: Q1 earnings is the main catalyst: Privia is scheduled to report Q1 results Thursday; investors will focus on revenue, patient volumes, margins and updated FY guidance — the release should determine the next directional move. Read More.
• Neutral Sentiment: Previews set expectations: recent previews outline items to watch (revenue mix, cost trends, value-based reimbursement progress); a clean beat could lift the stock, while conservative guidance could cap gains. Read More. Read More.
• Negative Sentiment: Insider sales by senior management: CFO David Mountcastle reported Rule 10b5‑1 sales (7,179 shares on May 1; 1,206 shares on May 4) — pre-arranged plans reduce governance concern but such disclosures can pressure near-term sentiment. Read More.
• Negative Sentiment: Director selling: Director Matthew Shawn Morris sold sizable blocks (17,096 on May 1 and 1,017 on May 4) under a 10b5‑1 plan, representing a material reduction in his position; this may weigh on sentiment despite the planned nature of the trades. Read More.

Institutional Trading of Privia Health Group

Several institutional investors and hedge funds have recently bought and sold shares of PRVA. Future Fund LLC boosted its stake in shares of Privia Health Group by 48.0% during the 1st quarter. Future Fund LLC now owns 65,538 shares of the company’s stock worth $1,348,000 after acquiring an additional 21,247 shares during the period. Financiere des Professionnels Fonds d investissement inc. bought a new stake in Privia Health Group in the 1st quarter valued at $229,000. Advisors Preferred LLC acquired a new stake in Privia Health Group during the 1st quarter valued at $1,696,000. Fifth Third Bancorp lifted its holdings in Privia Health Group by 1,047.1% during the 1st quarter. Fifth Third Bancorp now owns 38,142 shares of the company’s stock valued at $785,000 after purchasing an additional 34,817 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH bought a new position in Privia Health Group during the first quarter worth $3,900,000. Institutional investors own 94.48% of the company’s stock.

Analyst Ratings Changes

PRVA has been the subject of several analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Privia Health Group in a report on Friday, March 27th. Royal Bank Of Canada started coverage on Privia Health Group in a research report on Friday, January 9th. They set an “outperform” rating and a $31.00 price target for the company. Barclays raised their price target on Privia Health Group from $23.00 to $25.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 25th. Citigroup lowered their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Finally, Truist Financial upped their price objective on Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.31.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.